Cargando…

Targeting the Pro-Survival Protein MET with Tivantinib (ARQ 197) Inhibits Growth of Multiple Myeloma Cells()()

The hepatocyte growth factor (HGF)/MNNG HOS transforming gene (MET) pathway regulates cell growth, survival, and migration. MET is mutated or amplified in several malignancies. In myeloma, MET is not mutated, but patients have high plasma concentrations of HGF, high levels of MET expression, and gen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaman, Shadia, Shentu, Shujun, Yang, Jing, He, Jin, Orlowski, Robert Z., Stellrecht, Christine M., Gandhi, Varsha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372650/ https://www.ncbi.nlm.nih.gov/pubmed/25810013 http://dx.doi.org/10.1016/j.neo.2015.01.006

Ejemplares similares

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
por: Baljevic, Muhamed, et al.
Publicado: (2017)

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
por: Tolaney, Sara M., et al.
Publicado: (2015)

Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107
por: Twardowski, Przemyslaw W., et al.
Publicado: (2017)

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
por: Santoro, A, et al.
Publicado: (2013)

Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1
por: Lu, Shuai, et al.
Publicado: (2015)

Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines
por: Phillip, Cornel Joseph, et al.
Publicado: (2013)

Erratum to: Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines
por: Phillip, Cornel Joseph, et al.
Publicado: (2016)

ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo
por: Lath, Darren L., et al.
Publicado: (2018)

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
por: Azuma, Koichi, et al.
Publicado: (2016)

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
por: Eng, Cathy, et al.
Publicado: (2016)

Transmission of the atypical/Nor98 scrapie agent to Suffolk sheep with VRQ/ARQ, ARQ/ARQ, and ARQ/ARR genotypes
por: Cassmann, Eric D., et al.
Publicado: (2021)

The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis
por: Wang, Yubin, et al.
Publicado: (2023)

ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance
por: Gao, Xudong, et al.
Publicado: (2019)

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2017)

Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma
por: Wei, Kai, et al.
Publicado: (2019)

Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib
por: Agwa, Eberechi S, et al.
Publicado: (2014)

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
por: Wu, Zhuo-Xun, et al.
Publicado: (2020)

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors
por: Kummar, Shivaani, et al.
Publicado: (2021)

Development of Tivantinib as Treatment for Hepatocellular Carcinoma
por: Au, Jennifer, et al.
Publicado: (2013)

Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
por: Zhao, Shankun, et al.
Publicado: (2021)

ARQ20 : arquitectura en la España del siglo XX /
Publicado: (2006)

ARQ20 : arquitectura en la España del siglo XX.
Publicado: (2012)

In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
por: Yu, Yi, et al.
Publicado: (2017)

Strain Typing of Classical Scrapie and Bovine Spongiform Encephalopathy (BSE) by Using Ovine PrP (ARQ/ARQ) Overexpressing Transgenic Mice
por: Fatola, Olanrewaju I., et al.
Publicado: (2022)

A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma
por: Kudo, Masatoshi, et al.
Publicado: (2020)

ATP directed agent, 8-chloro-adenosine, induces AMP activated protein kinase activity, leading to autophagic cell death in breast cancer cells
por: Stellrecht, Christine M, et al.
Publicado: (2014)

Transmission of atypical scrapie to homozygous ARQ sheep
por: OKADA, Hiroyuki, et al.
Publicado: (2016)

Analysis of channel uncertainty in ARQ relay networks
por: Ajmal, Hina, et al.
Publicado: (2018)

Index Coded Automatic Repeat Request (ARQ)
por: Choi, Sang Won
Publicado: (2020)

Feinix-Arq: distribución GNU/LINUX a medida para la Facultad de Arquitectura de la Universidad Veracruzana /
por: Martínez Tovar, Víctor Daniel
Publicado: (2007)

Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study
por: Luo, Guang-li, et al.
Publicado: (2022)

Tivantinib alleviates inflammatory diseases by directly targeting NLRP3
por: Huang, Yi, et al.
Publicado: (2023)

ARQ531: the therapy that targets multiple pathways in acute myeloid leukemia
por: Hellmich, Charlotte, et al.
Publicado: (2020)

Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
por: Pievsky, Daniel, et al.
Publicado: (2016)

S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lee, Hans C., et al.
Publicado: (2023)

Combination of the c-Met Inhibitor Tivantinib and Zoledronic Acid Prevents Tumor Bone Engraftment and Inhibits Progression of Established Bone Metastases in a Breast Xenograft Model
por: Previdi, Sara, et al.
Publicado: (2013)

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia
por: Kuenzi, Brent M., et al.
Publicado: (2019)

Hybrid ARQ Scheme with Autonomous Retransmission for Multicasting in Wireless Sensor Networks
por: Jung, Young-Ho, et al.
Publicado: (2017)

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
por: Puzanov, Igor, et al.
Publicado: (2014)

The efficacy and safety of tivantinib in the treatment of solid tumors: a systematic review and meta-analysis
por: Zhang, Hao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dldg5efiojt634vgvltuslvqrf